 | • レポートコード：PMR210110 • 出版社/出版日：Persistence Market Research / 2020年11月19日 • レポート形態：英文、PDF、224ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User（1名用） | ￥676,200 (USD4,900) | ▷ お問い合わせ |
| Site Licence（同一拠点内共有可） | ￥1,048,800 (USD7,600) | ▷ お問い合わせ |
| Enterprise wide（複数拠点内共有可） | ￥1,462,800 (USD10,600) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Persistence Market Research社の本調査資料では、世界のトリプルネガティブ乳癌（TNBC）治療市場について調査し、エグゼクティブサマリー、市場概要、主要市場動向、市場背景、新型コロナウイルス感染症の影響分析、主要成功要因、価格分析、需要分析・予測、薬品種類別（ドキソルビシン、シクロホスファミド、パクリタキセル、ドセタキセル、カルボプラチン/シスプラチン）分析、流通チャネル別（病院、がん研究機関、リテールクリニック）分析、地域別分析、市場構造分析、競争分析、仮定、調査手法などを掲載しています。 ・エグゼクティブサマリー ・市場概要 ・主要市場動向 ・市場背景 ・新型コロナウイルス感染症の影響分析 ・主要成功要因 ・価格分析 ・需要分析・予測 ・世界のトリプルネガティブ乳癌（TNBC）治療市場規模：薬品種類別（ドキソルビシン、シクロホスファミド、パクリタキセル、ドセタキセル、カルボプラチン/シスプラチン） ・世界のトリプルネガティブ乳癌（TNBC）治療市場規模：流通チャネル別（病院、がん研究機関、リテールクリニック） ・世界のトリプルネガティブ乳癌（TNBC）治療市場規模：地域別 ・市場構造分析 ・競争分析 ・仮定 ・調査手法 |
Triple-Negative Breast Cancer Treatment Market – Scope of Report
A latest publication by Persistence Market Research (PMR) on the global triple-negative breast cancer treatment market evaluates the opportunities and current market landscape, and provides detailed analysis and updates about corresponding sections affecting the global triple-negative breast cancer treatment market. The study offers detailed insights on key market dynamics, which include the drivers, restraints, trends, opportunities in the triple-negative breast cancer treatment market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2020-2030.
Important indicators for the successful growth of the triple-negative breast cancer treatment market are presented in this comprehensive report, which include supply chain analysis, value chain analysis, Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR. This research study can support readers to know the demand for triple-negative breast cancer treatment and the quantitative development opportunities during the study period.
The research is beneficial for shareholders in the triple-negative breast cancer treatment market, including triple-negative breast cancer treatment market investors and service providers, and can help them in developing suitable business strategies for development in the market. Insights and findings presented in this PMR study can be leveraged by shareholders in the triple-negative breast cancer treatment market, industry experts, investors, researchers, reporters, as well as business enthusiasts.
Market statistics as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the triple-negative breast cancer treatment market are also included in the current study. Depending on potential developments in the triple-negative breast cancer treatment market, substantive insights are also encountered in this report. Additionally, by virtue of the data submitted in this triple-negative breast cancer treatment market report, minor companies and new entrants in the breast cancer treatment industry can be aided in making suitable company choices to achieve traction in the triple-negative breast cancer treatment market. Key Questions Answered in PMR’s Triple-negative Breast Cancer Treatment Market Report
Which regions will continue to remain the most profitable regional market for triple-negative breast cancer treatment market players?
Which factors will induce a change in the demand for breast cancer treatment during the assessment period?
How will COVID-19 change the trends of the triple-negative breast cancer treatment market?
How can market players capture the low-hanging opportunities in the triple-negative breast cancer treatment market in developed regions?
What are the winning strategies of stakeholders in the triple-negative breast cancer treatment market to upscale their position in this landscape?
What are the restraints that investors need to be aware of and tackle while investing in the triple-negative breast cancer treatment market?
What are the developmental trends in the triple-negative breast cancer treatment sectors that will impact the market?
How can businesses in the triple-negative breast cancer treatment market avail the growth opportunities in developed and emerging economies?
Triple-negative Breast Cancer Treatment Market: Research Methodology
In PMR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the triple-negative breast cancer treatment market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.
Secondary resources referred to by analysts during the production of the triple-negative breast cancer treatment market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts interviewed specialized industry experts, medical professionals related to triple-negative breast cancer treatment, and key executives of drug development and manufacturing companies, who contributed to the development of this report as a primary resource.
Comprehensive information assessment from primary and secondary resources acts as a validation from companies in the triple-negative breast cancer treatment market, and makes PMR’s projections on the growth prospects of the market more accurate and reliable.
レポート目次1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusion & Exclusion/ Scope of the Report
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Development Trends
3.3. Key Regulations
4. Market Background
4.1. Macro-Economic Factors
4.1.1. Global GDP Growth Outlook
4.1.2. Per Capita Healthcare Expenditure Outlook
4.1.1. Regional Healthcare Market Outlook
4.2. Forecast Factors – Relevance & Impact
4.2.1. Increasing Expenditure for Cancer Care
4.2.2. Growing Prevalence of Breast Cancer
4.2.3. Advancement in Cancer Treatment
4.2.4. New and Emerging Treatment Options
4.2.5. Potential in Generic Drugs
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity Analysis
4.4. Value Chain Analysis
5. COVID19 – Impact Analysis
5.1.1. Current COVID19 Statistics and Probable Future Impact
5.1.2. Current GDP Projection and Probable Impact
5.1.3. Current Economic Projection as compared to 2008 Economic analysis
5.1.4. COVID19 and Impact Analysis
5.1.4.1. Revenue By Drug Type
5.1.5. Projected Recovery Quarter
5.1.6. Recovery Scenario – Short term, Midterm and Long Term Impact
6. Key Success Factors.
6.1. Product Adoption / Usage Analysis
6.2. Key Promotional Strategies
6.3. Disease Epidemiology, Key Region
6.4. Reimbursement Guidelines
7. Global Triple-Negative Breast Cancer Treatment Market Pricing Analysis
7.1. Regional Pricing Analysis By Product Type
7.2. Pricing Break-up
7.2.1. Manufacturer Level Pricing
7.2.2. Distributor Level Pricing
8. Global Triple-Negative Breast Cancer Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2015-2019 and Forecast, 2020-2030
8.1. Historical Market Value (US$ Mn) Analysis, 2015-2019
8.2. Current and Future Market Value (US$ Mn) Projections, 2020-2030
8.2.1. Y-o-Y Growth Trend Analysis
8.2.2. Absolute $ Opportunity Analysis
9. Global Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Drug Type
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Drug Type, 2015 – 2019
9.3. Current and Future Market Size (US$ Mn) and Forecast By Drug Type, 2020 – 2030
9.3.1. Doxorubicin
9.3.2. Cyclophosphamide
9.3.3. Paclitaxel
9.3.4. Docetaxel
9.3.5. Carboplatin/Cisplatin
9.3.6. Others
9.4. Market Attractiveness Analysis Product
10. Global Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Distribution Channel
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2015 – 2019
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2020 – 2030
10.3.1. Hospitals
10.3.2. Cancer Research Institutes
10.3.3. Retail Clinics
10.4. Market Attractiveness Analysis By Distribution Channel
11. Global Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Region
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis By Region, 2015 – 2019
11.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2020 – 2030
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. South Asia
11.3.5. East Asia
11.3.6. Oceania
11.3.7. Middle East and Africa (MEA)
11.4. Market Attractiveness Analysis By Region
12. North America Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019
12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030
12.3.1. By Country
12.3.1.1. U.S.
12.3.1.2. Canada
12.3.2. By Drug Type
12.3.3. By Distribution Channel
12.4. Market Attractiveness Analysis
12.5. Market Trends
12.6. Key Market Participants – Intensity Mapping
12.7. Drivers and Restraints – Impact Analysis
13. Latin America Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019
13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030
13.3.1. By Country
13.3.1.1. Brazil
13.3.1.2. Mexico
13.3.1.3. Rest of Latin America
13.3.2. By Drug Type
13.3.3. By Distribution Channel
13.4. Market Attractiveness Analysis
13.5. Market Trends
13.6. Key Market Participants – Intensity Mapping
13.7. Drivers and Restraints – Impact Analysis
14. Europe Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019
14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030
14.3.1. By Country
14.3.1.1. Germany
14.3.1.2. Italy
14.3.1.3. France
14.3.1.4. U.K.
14.3.1.5. Spain
14.3.1.6. BENELUX
14.3.1.7. Russia
14.3.1.8. Rest of Europe
14.3.2. By Drug Type
14.3.3. By Distribution Channel
14.4. Market Attractiveness Analysis
14.5. Market Trends
14.6. Key Market Participants – Intensity Mapping
14.7. Drivers and Restraints – Impact Analysis
15. South Asia Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019
15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030
15.3.1. By Country
15.3.1.1. India
15.3.1.2. Thailand
15.3.1.3. Indonesia
15.3.1.4. Malaysia
15.3.1.5. Rest of South Asia
15.3.2. By Drug Type
15.3.3. By Distribution Channel
15.4. Market Attractiveness Analysis
15.5. Market Trends
15.6. Key Market Participants – Intensity Mapping
15.7. Drivers and Restraints – Impact Analysis
16. East Asia Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019
16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030
16.3.1. By Country
16.3.1.1. China
16.3.1.2. Japan
16.3.1.3. South Korea
16.3.2. By Drug Type
16.3.3. By Distribution Channel
16.4. Market Attractiveness Analysis
16.5. Market Trends
16.6. Key Market Participants – Intensity Mapping
16.7. Drivers and Restraints – Impact Analysis
17. Oceania Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019
17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030
17.3.1. By Country
17.3.1.1. Australia
17.3.1.2. New Zealand
17.3.2. By Drug Type
17.3.3. By Distribution Channel
17.4. Market Attractiveness Analysis
17.5. Market Trends
17.6. Key Market Participants – Intensity Mapping
17.7. Drivers and Restraints – Impact Analysis
18. Middle East and Africa Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019
18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030
18.3.1. By Country
18.3.1.1. GCC Countries
18.3.1.2. Turkey
18.3.1.3. Northern Africa
18.3.1.4. South Africa
18.3.1.5. Rest of Middle East and Africa
18.3.2. By Drug Type
18.3.3. By Distribution Channel
18.4. Market Attractiveness Analysis
18.5. Market Trends
18.6. Key Market Participants – Intensity Mapping
18.7. Drivers and Restraints – Impact Analysis
19. Key and Emerging Countries Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030
19.1. Introduction
19.1.1. Market Value Proportion Analysis, By Key Countries
19.1.2. Global Vs. Country Growth Comparison
19.2. U.S. Triple-Negative Breast Cancer Treatment Market Analysis
19.2.1. By Drug Type
19.2.2. By Distribution Channel
19.3. Canada Triple-Negative Breast Cancer Treatment Market Analysis
19.3.1. By Drug Type
19.3.2. By Distribution Channel
19.4. Brazil Triple-Negative Breast Cancer Treatment Market Analysis
19.4.1. By Drug Type
19.4.2. By Distribution Channel
19.5. Mexico Triple-Negative Breast Cancer Treatment Market Analysis
19.5.1. By Drug Type
19.5.2. By Distribution Channel
19.6. Germany Triple-Negative Breast Cancer Treatment Market Analysis
19.6.1. By Drug Type
19.6.2. By Distribution Channel
19.7. Italy Triple-Negative Breast Cancer Treatment Market Analysis
19.7.1. By Drug Type
19.7.2. By Distribution Channel
19.8. France Triple-Negative Breast Cancer Treatment Market Analysis
19.8.1. By Drug Type
19.8.2. By Distribution Channel
19.9. U.K. Triple-Negative Breast Cancer Treatment Market Analysis
19.9.1. By Drug Type
19.9.2. By Distribution Channel
19.10. Spain Triple-Negative Breast Cancer Treatment Market Analysis
19.10.1. By Drug Type
19.10.2. By Distribution Channel
19.11. BENELUX Triple-Negative Breast Cancer Treatment Market Analysis
19.11.1. By Drug Type
19.11.2. By Distribution Channel
19.12. Russia Triple-Negative Breast Cancer Treatment Market Analysis
19.12.1. By Drug Type
19.12.2. By Distribution Channel
19.13. India Triple-Negative Breast Cancer Treatment Market Analysis
19.13.1. By Drug Type
19.13.2. By Distribution Channel
19.14. Thailand Triple-Negative Breast Cancer Treatment Market Analysis
19.14.1. By Drug Type
19.14.2. By Distribution Channel
19.15. Indonesia Triple-Negative Breast Cancer Treatment Market Analysis
19.15.1. By Drug Type
19.15.2. By Distribution Channel
19.16. Malaysia Triple-Negative Breast Cancer Treatment Market Analysis
19.16.1. By Drug Type
19.16.2. By Distribution Channel
19.17. China Triple-Negative Breast Cancer Treatment Market Analysis
19.17.1. By Drug Type
19.17.2. By Distribution Channel
19.18. Japan Triple-Negative Breast Cancer Treatment Market Analysis
19.18.1. By Drug Type
19.18.2. By Distribution Channel
19.19. South Korea Triple-Negative Breast Cancer Treatment Market Analysis
19.19.1. By Drug Type
19.19.2. By Distribution Channel
19.20. Australia Triple-Negative Breast Cancer Treatment Market Analysis
19.20.1. By Drug Type
19.20.2. By Distribution Channel
19.21. New Zealand Triple-Negative Breast Cancer Treatment Market Analysis
19.21.1. By Drug Type
19.21.2. By Distribution Channel
19.22. GCC Countries Triple-Negative Breast Cancer Treatment Market Analysis
19.22.1. By Drug Type
19.22.2. By Distribution Channel
19.23. Turkey Triple-Negative Breast Cancer Treatment Market Analysis
19.23.1. By Drug Type
19.23.2. By Distribution Channel
19.24. Northern Africa Triple-Negative Breast Cancer Treatment Market Analysis
19.24.1. By Drug Type
19.24.2. By Distribution Channel
19.25. South Africa Triple-Negative Breast Cancer Treatment Market Analysis
19.25.1. By Drug Type
19.25.2. By Distribution Channel
20. Market Structure Analysis
20.1. Market Structure Analysis by Tier of Companies
20.2. Market Share Analysis for Top Players
20.3. Market Concentration
20.4. Market Presence Analysis
20.4.1. By Regional footprint of Players
20.4.2. Product foot print by Players
20.4.3. Channel Foot Print by Players
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
21.3.1. AstraZeneca plc.
21.3.1.1. Overview
21.3.1.2. Product Portfolio
21.3.1.3. Profitability by Market Segments (Product/Channel/Region)
21.3.1.4. Sales Footprint
21.3.1.5. Strategy Overview
21.3.1.5.1. Marketing Strategy
21.3.1.5.2. Product Strategy
21.3.1.5.3. Channel Strategy
21.3.2. Pfizer, Inc.
21.3.2.1. Overview
21.3.2.2. Product Portfolio
21.3.2.3. Profitability by Market Segments (Product/Channel/Region)
21.3.2.4. Sales Footprint
21.3.2.5. Strategy Overview
21.3.2.5.1. Marketing Strategy
21.3.2.5.2. Product Strategy
21.3.2.5.3. Channel Strategy
21.3.3. F. Hoffman – La Roche Ltd.
21.3.3.1. Overview
21.3.3.2. Product Portfolio
21.3.3.3. Profitability by Market Segments (Product/Channel/Region)
21.3.3.4. Sales Footprint
21.3.3.5. Strategy Overview
21.3.3.5.1. Marketing Strategy
21.3.3.5.2. Product Strategy
21.3.3.5.3. Channel Strategy
21.3.4. Bristol-Myers Squibb Company
21.3.4.1. Overview
21.3.4.2. Product Portfolio
21.3.4.3. Profitability by Market Segments (Product/Channel/Region)
21.3.4.4. Sales Footprint
21.3.4.5. Strategy Overview
21.3.4.5.1. Marketing Strategy
21.3.4.5.2. Product Strategy
21.3.4.5.3. Channel Strategy
21.3.5. Novartis AG
21.3.5.1. Overview
21.3.5.2. Product Portfolio
21.3.5.3. Profitability by Market Segments (Product/Channel/Region)
21.3.5.4. Sales Footprint
21.3.5.5. Strategy Overview
21.3.5.5.1. Marketing Strategy
21.3.5.5.2. Product Strategy
21.3.5.5.3. Channel Strategy
21.3.6. Mylan N.V.
21.3.6.1. Overview
21.3.6.2. Product Portfolio
21.3.6.3. Profitability by Market Segments (Product/Channel/Region)
21.3.6.4. Sales Footprint
21.3.6.5. Strategy Overview
21.3.6.5.1. Marketing Strategy
21.3.6.5.2. Product Strategy
21.3.6.5.3. Channel Strategy
21.3.7. Eli Lilly and Company
21.3.7.1. Overview
21.3.7.2. Product Portfolio
21.3.7.3. Profitability by Market Segments (Product/Channel/Region)
21.3.7.4. Sales Footprint
21.3.7.5. Strategy Overview
21.3.7.5.1. Marketing Strategy
21.3.7.5.2. Product Strategy
21.3.7.5.3. Channel Strategy
21.3.8. Celgene Corporation
21.3.8.1. Overview
21.3.8.2. Product Portfolio
21.3.8.3. Profitability by Market Segments (Product/Channel/Region)
21.3.8.4. Sales Footprint
21.3.8.5. Strategy Overview
21.3.8.5.1. Marketing Strategy
21.3.8.5.2. Product Strategy
21.3.8.5.3. Channel Strategy
21.3.9. Sanofi S.A.
21.3.9.1. Overview
21.3.9.2. Product Portfolio
21.3.9.3. Profitability by Market Segments (Product/Channel/Region)
21.3.9.4. Sales Footprint
21.3.9.5. Strategy Overview
21.3.9.5.1. Marketing Strategy
21.3.9.5.2. Product Strategy
21.3.9.5.3. Channel Strategy
21.3.10. Johnson & Johnson Services, Inc.
21.3.10.1. Overview
21.3.10.2. Product Portfolio
21.3.10.3. Profitability by Market Segments (Product/Channel/Region)
21.3.10.4. Sales Footprint
21.3.10.5. Strategy Overview
21.3.10.5.1. Marketing Strategy
21.3.10.5.2. Product Strategy
21.3.10.5.3. Channel Strategy
22. Assumptions and Acronyms Used
23. Research Methodology
Table 01: Global Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug TypeTable 02: Global Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Distribution Channel
Table 03: Global Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Region
Table 04: North America Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country
Table 05: North America Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Type
Table 06: North America Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Distribution Channel
Table 07: Latin America Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country
Table 08: Latin America Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Type
Table 09: Latin America Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Distribution Channel
Table 10: Europe Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country
Table 11: Europe Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Type
Table 12: Europe Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Distribution Channel
Table 13: South Asia Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country
Table 14: South Asia Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Type
Table 15: South Asia Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Distribution Channel
Table 16: East Asia Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country
Table 17: East Asia Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Type
Table 18: East Asia Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Distribution Channel
Table 19: Oceania Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country
Table 20: Oceania Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Type
Table 21: Oceania Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Distribution Channel
Table 22: Middle East and Africa Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country
Table 23: Middle East and Africa Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Type
Table 24: Middle East and Africa Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Distribution Channel